Advanced Science | Anti-EGFR Nanobody-Mediated Delivery of RIBOTACs for miR-21 Degradation in Pancreatic Cancer Therapy

This study provides a novel RNA-targeted degradation strategy for pancreatic cancer treatment. By utilizing an EGFR-mediated precision delivery system, it addresses the critical challenge of traditional nucleic acid drugs failing to penetrate the dense stromal barrier of tumors, offering key experimental design references for related drug development.

 

Literature Overview

The article titled "Cell-Selective Delivery of RIBOTACs via an Anti-EGFR Nanobody for Pancreatic Cancer Treatment," published in Advanced Science, systematically explores the use of oncogenic miRNA-21, identified through bioinformatics screening, as a therapeutic target. By combining anti-EGFR nanobodies with enzyme-responsive RIBOTAC technology, the study constructs a novel nanomedicine capable of penetrating dense stroma and selectively degrading miR-21.

Background Knowledge

Pancreatic ductal adenocarcinoma (PDAC) remains a formidable therapeutic challenge due to its dense fibrotic stroma and lack of druggable targets, resulting in poor patient prognosis. miR-21, a significantly overexpressed oncogenic microRNA in various gastrointestinal cancers, drives tumor progression by suppressing tumor suppressor genes such as PTEN and PDCD4. However, targeting miR-21 faces two major bottlenecks: delivery difficulties and off-target toxicity. Traditional antisense oligonucleotides or small interfering RNAs struggle to penetrate the stromal barrier of PDAC and lack cell specificity. This study leverages the small size and high penetrability of nanobodies, combined with the high expression of EGFR in PDAC, to design a dual-targeting strategy: EGFR-mediated cellular uptake delivers the payload into tumor cells, followed by the cleavage of a Val-Cit linker by Cathepsin B, which is highly expressed in the tumor microenvironment, releasing active RIBOTACs for precise miR-21 degradation.

 

 

Research Methods and Core Experiments

Authors first identified miR-21 as a key target by integrating pan-gastrointestinal cancer analyses from public databases (TCGA) and their own cohorts. Subsequently, they constructed an Nb-RIBOTAC conjugate composed of an anti-EGFR nanobody (Nb-Fc fusion), a Cathepsin B-responsive Val-Cit linker, and a miR-21-targeting RIBOTAC module. In vitro experiments using EGFR-high (e.g., PANC-1) and EGFR-low (e.g., KLM) PDAC cell lines, along with normal pancreatic cells (HPNE), demonstrated that the conjugate effectively degraded miR-21 and restored PDCD4 protein expression only in EGFR-high cells. Confocal microscopy confirmed endocytosis and lysosomal localization within 6 hours.

In vivo efficacy evaluation utilized a PANC-1 orthotopic xenograft mouse model. Live fluorescence imaging confirmed that Nb-RIBOTAC rapidly penetrated the stroma and accumulated in the tumor site within 3 hours post-injection, peaking at 48 hours. Efficacy studies showed that administering the drug every 48 hours significantly inhibited tumor growth, with an inhibition rate far exceeding the gemcitabine control group. No significant weight loss or abnormalities in liver and kidney toxicity markers were observed, demonstrating an excellent therapeutic index and biocompatibility.

Key Conclusions and Perspectives

• miR-21 is significantly overexpressed in PDAC and strongly correlated with poor prognosis, representing a highly promising therapeutic target, though delivery challenges must be addressed.
• The constructed Nb-RIBOTAC conjugate achieved over 60% miR-21 knockdown in EGFR-high PDAC cells while fully preserving normal cell viability.
• This strategy successfully overcomes the physical barrier of the dense PDAC stroma through EGFR-mediated endocytosis and Cathepsin B-responsive release mechanisms, achieving tumor-selective drug activation.
• In vivo experiments confirmed that Nb-RIBOTAC effectively restores PDCD4 expression and induces tumor cell apoptosis. Its anti-tumor efficacy surpasses the first-line clinical drug gemcitabine, with no systemic toxicity.

Research Significance and Prospects

This study not only offers a novel solution for treating "undruggable" targets in pancreatic cancer but also establishes a universal paradigm of "bioinformatics screening + nanobody delivery + enzyme-responsive release." This strategy can be extended to other RNA targets difficult to deliver in solid tumors, providing a new technical pathway for drug development. Furthermore, its superior penetration and safety profile suggest broad application prospects in clinical monitoring and combination therapies, with the potential to improve survival rates for PDAC patients.

 

 

Conclusion

This study successfully developed an anti-EGFR nanobody-mediated RIBOTAC conjugate that achieves significant anti-tumor effects in pancreatic cancer models by precisely targeting and degrading oncogenic miR-21. The research not only validates the feasibility of RNA degradation technology in solid tumor therapy but also, through ingenious molecular design, solves the challenges of drug penetration through the stroma and specific activation. From the perspective of laboratory-to-clinical translation, this modular and customizable delivery system lays a crucial foundation for the care systems of related diseases. It provides effective intervention手段 for oncogenic non-coding RNAs that are difficult to reach with traditional small molecules or antibody drugs, holding extremely high clinical translation value and broad promotion prospects.

 

Tianli Luo, Yijuan Wang, Dengwang Chen, Feng Gao, and Xin Wang. Cell‐Selective Delivery of RIBOTACs via an Anti‐EGFR Nanobody for Pancreatic Cancer Treatment. Advanced Science.